Crescita Therapeutics Stock Performance
| CRRTF Stock | USD 0.45 0.00 0.00% |
Crescita Therapeutics holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -29.73, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Crescita Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Crescita Therapeutics is expected to outperform it. Use Crescita Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and rate of daily change , to analyze future returns on Crescita Therapeutics.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Crescita Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, Crescita Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 14.3 M | |
| Total Cashflows From Investing Activities | -846 K |
Crescita |
Crescita Therapeutics Relative Risk vs. Return Landscape
If you would invest 2.10 in Crescita Therapeutics on August 29, 2024 and sell it today you would earn a total of 42.90 from holding Crescita Therapeutics or generate 2042.86% return on investment over 90 days. Crescita Therapeutics is currently producing 15.8433% returns and takes up 125.9961% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Crescita, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Crescita Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crescita Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Crescita Therapeutics, and traders can use it to determine the average amount a Crescita Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1257
| Best Portfolio | Best Equity | CRRTF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 126.0 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Crescita Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crescita Therapeutics by adding it to a well-diversified portfolio.
Crescita Therapeutics Fundamentals Growth
Crescita Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Crescita Therapeutics, and Crescita Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Crescita Pink Sheet performance.
| Return On Equity | 0.0318 | |||
| Return On Asset | 0.0227 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 3.64 M | |||
| Shares Outstanding | 20.4 M | |||
| Price To Earning | 490.00 X | |||
| Price To Book | 0.66 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 16.77 M | |||
| EBITDA | 606 K | |||
| Cash And Equivalents | 10.5 M | |||
| Cash Per Share | 0.51 X | |||
| Total Debt | 1.71 M | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (1.6 M) | |||
| Earnings Per Share | 0.02 X | |||
| Total Asset | 28.92 M | |||
About Crescita Therapeutics Performance
By analyzing Crescita Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Crescita Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Crescita Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Crescita Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada. Crescita Therapeutics is traded on OTC Exchange in the United States.Things to note about Crescita Therapeutics performance evaluation
Checking the ongoing alerts about Crescita Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Crescita Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Crescita Therapeutics is way too risky over 90 days horizon | |
| Crescita Therapeutics has some characteristics of a very speculative penny stock | |
| Crescita Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 16.77 M. Net Loss for the year was (1.1 M) with profit before overhead, payroll, taxes, and interest of 10.01 M. | |
| Crescita Therapeutics has accumulated about 10.5 M in cash with (1.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from businesswire.com: Acquisition by Paul Wagner of 31250 shares of Forte Biosciences subject to Rule 16b-3 |
- Analyzing Crescita Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Crescita Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Crescita Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Crescita Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Crescita Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Crescita Therapeutics' pink sheet. These opinions can provide insight into Crescita Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Crescita Pink Sheet analysis
When running Crescita Therapeutics' price analysis, check to measure Crescita Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crescita Therapeutics is operating at the current time. Most of Crescita Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crescita Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crescita Therapeutics' price. Additionally, you may evaluate how the addition of Crescita Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |